CRNX - Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why | Benzinga
Tuesday, Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) released topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of paltusotine for acromegaly.
Acromegaly is a hormonal disorder that develops when the pituitary gland produces too much growth hormone during adulthood.
The 111-participant study met statistical significance (p<0.0001) on the primary endpoint, based on the proportion of participants taking paltusotine (56%) who achieved an insulin-like growth factor 1 (IGF-1) ...